{"name":"Phio Pharmaceuticals Inc.","slug":"phio-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"Phio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel RNA-targeting therapeutics. The company's lead candidate, PH-762, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":4618000,"netIncome":-8698000,"cash":21031000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PH-762","genericName":"PH-762","slug":"ph-762","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"PH-762","genericName":"PH-762","slug":"ph-762","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-04-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPblRvcGpCRC1RcmRTenRTMy11ZFlWSDczeFN5UENKT3Nzb3diVW9mMkd2dURweVhNV2NNZEt0STJ2ZXhEQVNZMFBXYXhUSlFpTFg4bmVDdWMxTm9lUk5ua082bDNUSGlXRWE2cmwxS0l0NWNxWE45TERVZHZseGp1elI4aFIycm0tTWl1NzR4WFBkTVFCVEx6QjJZa3B2MzdVNXYybEJuZVFqQldfc2d4UEdKZ05Ld01ITnN6bnFKaw?oc=5","date":"2026-03-10","type":"trial","source":"Stock Titan","summary":"Cancer gene-silencing trial shows 65% response in Phio study - Stock Titan","headline":"Cancer gene-silencing trial shows 65% response in Phio study","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNVmtRbVpWeXJBbV9nMEhTTmNudTJ1Rl9WNURQQS0xLUF5NTN2VWE4MENVbDVDekRFSHlQOWU0c2JUdW9VTVZ0TkMxVkpfTUFWZERBZFJCVEltbTgzVDVTT3g3S2tKVlAtRk1aSlJkMkpVSnRVcDdaV2JBdm5PeEVLQ1hoS0IxZjJjMlJaWHZSYzlCeWs?oc=5","date":"2026-02-19","type":"pipeline","source":"Yahoo Finance","summary":"Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 - Yahoo Finance","headline":"Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE1nRDcxMVpJU0hUUUVoc2wxOFhJQk41bkJQTG1sUE4zS0ItNzJHaDQzNzlQdEp6YVFoX2dPV1JieHJ6LUYwajJVTlR0bzczNjFLa2F1ZWhHOG5RS3pkS1HSAWNBVV95cUxQV2g3aGdTMG8xeEpoTGM5RWMtdHhXbjJ3dUhQTTZUVDhrSzAwdVFhV1FSelg1Q0tpdXVieENZR2NKaGpkT0xjMWNVRlJkRzRUNURKZzR1SzkweDFRdzgxOEFNREk?oc=5","date":"2026-02-12","type":"pipeline","source":"Bitget","summary":"What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Bitget","headline":"What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPUU5SY2FNU0V0S3pwMGVMenFkLTU3d1VLZ2lrM1FoZHdjWVBXMThVNUVxRG01ZGhJdXNZYWFnUUNSekdGa0ZqS25YQXRZZ0w3elFNWlJTd3p1Q044TklZUDlrbjBOWXhnUVhTWDJJTElEMzVGV1llZmlScDFWZ2VKNUZLYWJxOEJhTWNxUmIyajNLdTlNVW9kSHE0ckZvVkF5alEzNm9LU01WN25QdTdlYWM1RWlIMGd0Z0ZqbWZKUWg?oc=5","date":"2026-02-10","type":"trial","source":"Stock Titan","summary":"Top PH-762 skin cancer dose triggers 85% tumor response in Phio trial - Stock Titan","headline":"Top PH-762 skin cancer dose triggers 85% tumor response in Phio trial","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQSmxaVDB2N2ExWDgxWE5rbWtiYzM5M1pIbzBlZGNYYUN5ZzJCWl9XMldqQ0FwNjhMRXIwSmx4MDVmbUZmRjZ6aVVKckNiOXJXcWVlQVlfVEwtQXB3X2h2Qnc1UFUxUk5vZFZKdTJpbG9EbURZSHBRNXpGbS1DUWpJdXI4T1daaEFpT1VkV3gzaVVCWVNCQ01sTE56dlVnbThYNHZvbnpzM2F1U1owUUJNWkJfQ1JWV3B2Y1E?oc=5","date":"2026-01-20","type":"pipeline","source":"Stock Titan","summary":"Phio cancer drug clears tumors in 10 of 14, no dose-limiting toxicities - Stock Titan","headline":"Phio cancer drug clears tumors in 10 of 14, no dose-limiting toxicities","sentiment":"neutral"},{"date":"2026-01-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOalppcll5MXRsNG1TMV9xRUlSR0RTQTRBSlRSQlRJVjR4U2NzM3FULUtpcFFYRGhHTFZxaG4zclI3UWtUcVBqWGdaa0g0RTNFaGpzb2Jwcy1LaTdWME9vUmtqV01EMDRnOU5lZTFIM1Vocm81cTE2VXJRMGV5Y1FVMkRmLUd5NHRpbWpHTVdxcktkeHpyZDctTzlTckk4cUNjUFFwVGlZUlNjdFBOQnhwUTFFRGtCVkYyckFDQ2N5OA?oc=5","date":"2025-12-23","type":"trial","source":"Stock Titan","summary":"Early PH-762 skin cancer trial sees full tumor clearance in some patients - Stock Titan","headline":"Early PH-762 skin cancer trial sees full tumor clearance in some patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOaWRTd25RTVowZjhwcUdkWU9YQWp6UUptdGRQME9yd08yMS1yUUN1SmN4ckMza3NLRmpEdVlTZFBUM2tXWFZXMzZZVzAzWkFsSEFMZDg1SXlkdVR2VXRYTFg2aThhNzMyaTZ0RFpzSjBfamdSRTJxTDFZVFR0QVRXa3liSWZ6Y2tRU28wbUxkMUVYMXd5MC1lblNBVHQ4cVBZX2djajlUTlo4ZTh4QkZUMlRGUmtyZjBpVDlPZ2kyS3lZVXdaR3QwbkVucTh5YnVqSVlkVFBUODg?oc=5","date":"2025-12-23","type":"pipeline","source":"TMX Newsfile","summary":"Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 - TMX Newsfile","headline":"Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":0,"period":"2020-12-31"},{"value":21000,"period":"2019-12-31"},{"value":138000,"period":"2018-12-31"},{"value":15000,"period":"2017-12-31"},{"value":19000,"period":"2016-12-31"},{"value":34000,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":4618000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-8698000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":21031000,"cashHistory":[],"totalAssets":21487000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}